IL232385A - Use of Halopnate or Cephalic Acid Compounds to Treat Hyperoricemia in Patients with Gout, Hyperoricemia, or Renal Disorder - Google Patents
Use of Halopnate or Cephalic Acid Compounds to Treat Hyperoricemia in Patients with Gout, Hyperoricemia, or Renal DisorderInfo
- Publication number
- IL232385A IL232385A IL232385A IL23238514A IL232385A IL 232385 A IL232385 A IL 232385A IL 232385 A IL232385 A IL 232385A IL 23238514 A IL23238514 A IL 23238514A IL 232385 A IL232385 A IL 232385A
- Authority
- IL
- Israel
- Prior art keywords
- hyperuricemia
- halofenate
- gout
- medicaments
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/059425 WO2013066352A1 (en) | 2011-11-04 | 2011-11-04 | Methods for treating gout in patient subpopulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL232385A0 IL232385A0 (en) | 2014-06-30 |
| IL232385A true IL232385A (en) | 2017-10-31 |
Family
ID=48192536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL232385A IL232385A (en) | 2011-11-04 | 2014-04-30 | Use of Halopnate or Cephalic Acid Compounds to Treat Hyperoricemia in Patients with Gout, Hyperoricemia, or Renal Disorder |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2775835A4 (zh) |
| JP (1) | JP6047172B2 (zh) |
| KR (1) | KR101848122B1 (zh) |
| CN (1) | CN104066323A (zh) |
| AU (1) | AU2011380509B2 (zh) |
| BR (1) | BR112014010693A2 (zh) |
| CA (1) | CA2859689C (zh) |
| CL (1) | CL2014001156A1 (zh) |
| IL (1) | IL232385A (zh) |
| MX (1) | MX354846B (zh) |
| NZ (1) | NZ624714A (zh) |
| SG (1) | SG11201402027PA (zh) |
| WO (1) | WO2013066352A1 (zh) |
| ZA (1) | ZA201403574B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013245675B2 (en) * | 2012-04-13 | 2017-02-09 | Cymabay Therapeutics, Inc. | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent |
| CN104068288B (zh) * | 2014-07-25 | 2016-08-24 | 许伟琦 | 一种防尿路结石的饲料添加剂 |
| CN105920022A (zh) * | 2016-05-12 | 2016-09-07 | 成都易创思生物科技有限公司 | 一种抗痛风药物复方制剂 |
| EP3701952A4 (en) * | 2017-10-26 | 2021-06-30 | Otsuka Pharmaceutical Co., Ltd. | INOSITE PHOSPHATE COMPOSITION |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4250191A (en) * | 1978-11-30 | 1981-02-10 | Edwards K David | Preventing renal failure |
| US6262118B1 (en) | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| BRPI0819847B1 (pt) * | 2007-11-27 | 2022-01-11 | Ardea Biosciences, Inc | Compostos e composições |
-
2011
- 2011-11-04 EP EP11875027.2A patent/EP2775835A4/en not_active Withdrawn
- 2011-11-04 SG SG11201402027PA patent/SG11201402027PA/en unknown
- 2011-11-04 NZ NZ624714A patent/NZ624714A/en not_active IP Right Cessation
- 2011-11-04 JP JP2014541012A patent/JP6047172B2/ja not_active Expired - Fee Related
- 2011-11-04 CN CN201180076189.7A patent/CN104066323A/zh active Pending
- 2011-11-04 AU AU2011380509A patent/AU2011380509B2/en not_active Ceased
- 2011-11-04 KR KR1020147015209A patent/KR101848122B1/ko active IP Right Grant
- 2011-11-04 BR BR112014010693-2A patent/BR112014010693A2/pt not_active IP Right Cessation
- 2011-11-04 CA CA2859689A patent/CA2859689C/en not_active Expired - Fee Related
- 2011-11-04 MX MX2014005399A patent/MX354846B/es active IP Right Grant
- 2011-11-04 WO PCT/US2011/059425 patent/WO2013066352A1/en active Application Filing
-
2014
- 2014-04-30 IL IL232385A patent/IL232385A/en active IP Right Grant
- 2014-05-02 CL CL2014001156A patent/CL2014001156A1/es unknown
- 2014-05-16 ZA ZA2014/03574A patent/ZA201403574B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX354846B (es) | 2018-03-22 |
| CL2014001156A1 (es) | 2015-01-16 |
| CA2859689A1 (en) | 2013-05-10 |
| AU2011380509B2 (en) | 2016-05-19 |
| BR112014010693A2 (pt) | 2020-11-10 |
| NZ624714A (en) | 2016-01-29 |
| CA2859689C (en) | 2018-05-22 |
| EP2775835A4 (en) | 2015-07-29 |
| ZA201403574B (en) | 2015-11-25 |
| IL232385A0 (en) | 2014-06-30 |
| WO2013066352A1 (en) | 2013-05-10 |
| KR101848122B1 (ko) | 2018-04-11 |
| EP2775835A1 (en) | 2014-09-17 |
| SG11201402027PA (en) | 2014-09-26 |
| MX2014005399A (es) | 2015-04-08 |
| CN104066323A (zh) | 2014-09-24 |
| JP6047172B2 (ja) | 2016-12-21 |
| KR20140123927A (ko) | 2014-10-23 |
| AU2011380509A1 (en) | 2014-05-29 |
| JP2014532759A (ja) | 2014-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2014007533A0 (en) | Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases | |
| ZA201403795B (en) | Formulations for the treatment of diabetes | |
| IL232251B (en) | Pharmaceutical combination for use in the treatment of type 2 diabetes patients | |
| HK1196819A1 (zh) | 雜環化合物、含有所述化合物的藥物及其用途和其製備方法 | |
| IL232384A (en) | Use of lupanate compounds or lupanic acid for the preparation of anti-gout drugs | |
| IL223289A0 (en) | Treatment of type 2 diabetes | |
| HUS2000020I1 (hu) | Ciklezonid a légúti betegségek kezelésére lovaknál | |
| IL233351A (en) | Use of apolipoprotein a – iv without glycosylation for the preparation of diabetes medications | |
| IL232385A (en) | Use of Halopnate or Cephalic Acid Compounds to Treat Hyperoricemia in Patients with Gout, Hyperoricemia, or Renal Disorder | |
| ZA201403575B (en) | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | |
| PT2560662T (pt) | Sulodexide para a utilização no tratamento de patologias nas quais as metaloproteínases estão envolvidas | |
| IL228891A (en) | 3-carboxylic salts-n-ethyl n, n-dimethylpropane-1-amine for use in the treatment of cardiovascular disease | |
| IL221747A (en) | Inhibits Sodium / Phosphate Co-Transmission through the Aryl Fluorophosphate Peripheral Membrane | |
| DK2656075T3 (da) | Fremgangsmåde til optimering af behandlingen af patienter med biologiske lægemidler | |
| HK1196953A1 (zh) | 用於治療糖尿病的製劑 | |
| SG10201609202PA (en) | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | |
| ZA201307614B (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease | |
| GB201009893D0 (en) | Electrochemical reactor for the treatment of fluids | |
| PL391810A1 (pl) | Nowe sole ziprasidonu oraz sposoby ich otrzymywania |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |